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Abstract 
Objective The purpose of this study was to evaluate the 
effect of Cox-2 administration on direct (primary) fracture 
healing. 
Methods A transverse tibial osteotomy was created in 
adult male rabbits and rigidly ﬁxed in compression using a 
2.7-mm dynamic compression plate. Animals were ran-
domized to receive either rofecoxib (12.5 mg orally per 
process 
day) or placebo. Animals were killed at 4 weeks and 
fracture healing assessed by mechanical testing. 
Results There were no signiﬁcant differences between 
the control and Cox-2 treated animals in terms of 
mechanical strength at 4 weeks. There was a high com­
plication rate of peri-implant fractures during the daily 
medication administration. 
Conclusion The immediate administration of a Cox-2 
speciﬁc inhibitor did not impair primary (direct) bone 
healing at the dose administered in this rabbit tibial oste­
otomy model. 
Introduction 
Fracture healing has classically been divided into either 
primary (direct) or secondary fracture healing. Primary 
fracture healing occurs when the cortex is anatomically 
reduced and rigidly ﬁxed with a compression plate. The 
involves osteoclasts in cutting cones crossing 
the fracture site and forming new osteons that bridge the 
fracture gap. In comparison, secondary bone healing occurs 
when there is relative motion between the fracture frag­
ments and a large external callus is formed with subsequent 
endochondral and intramembranous bone formation. 
The majority of preclinical studies have shown that non­
speciﬁc non-steroidal anti-inﬂammatory drugs (NSAIDs) 
impair secondary bone healing [1–4]. Several studies have 
also shown that a speciﬁc class of NSAIDs, cyclooxygen­
ase-2 (Cox-2) speciﬁc inhibitors, delays healing and 
decreases fracture strength in animal models that heal by 
secondary bone healing [5–8]. These studies have exam­
ined the effect of Cox-2 inhibitors in a standard rat femoral 
fracture model in which the femur was loosely stabilized 
with a non-locked intramedullary k-wire. This method of 
ﬁxation permits residual motion at the fracture site, and the 
fracture heals through the production of callus and sec­
ondary (indirect) bone healing. Other studies have shown 
that the administration of both nonspeciﬁc and speciﬁc 
Cox-2 inhibitors decreased the number of osteoclast-like 
cells in a bone ingrowth model [9]. Since osteoclasts play a 
critical role in primary bone healing, their impairment by 
Cox-2 inhibitors may conceivably lead to impaired primary 
(direct) bone healing. 
Prior to the widespread publicity about increased cardiac 
complications associated with the use of certain Cox-2 
inhibitors, Cox-2 inhibitors had become widely prescribed 
for common orthopedic conditions, and their use had been 
advocated as part of a multi-modality approach for postop­
erative pain control [10–15]. Following fracture ﬁxation 
there is said to be a race between fracture healing and failure 
of ﬁxation. If Cox-2 speciﬁc inhibitors impair primary 
(direct) bone healing, their use following rigid internal ﬁx­
ation of fractures might lead to ﬁxation failure and nonunion. 
The purpose of this study was to investigate whether Cox-2 
inhibitors impair primary (direct) bone healing in fractures 
that are anatomically reduced and rigidly ﬁxed. 
Methods 
Animal model 
One-year-old skeletally mature male New Zealand White 
rabbits were used under a protocol approved by our Institu­
tional Animal Use and Care Committee. Animals ranged in 
weight from 3.0 to 3.5 kg with similar mean weights between 
the two groups. Anesthesia was initiated with a SQ injection 
of ketamine (50 mg/kg), xylazine (5 mg/kg) and AcePro­
mazine (0.5 mg/kg), and maintained with alternating IV 
injections of ketamine (20 mg) and xylazine (2 mg) as nee­
ded. An intravenous catheter was inserted into the dorsal ear 
vein and 0.9% sodium chloride or LRS infused throughout 
the procedure (10 mg/kg/min). The antibiotic Baytril 
(10 mg/kg) was administered IM preoperatively. Postopera­
tively the animals received Buprenorphine IM (0.01 mg/kg) 
and Baytril IM (10 mg/kg) every 12 h for 3 days. 
The animals right hindlimb was prepped with betadine 
and sterilely draped. A longitudinal incision was made over 
the anterior tibial crest. A saline-cooled oscillating saw was 
used to produce a transverse mid-diaphyseal tibial osteot­
omy to simulate a fracture [16]. The osteotomy was ana­
tomically reduced and internally ﬁxed in compression with 
a six-hole, 2.7-mm dynamic compression plate (Synthes, 
Paoli, PA) and six bicortical screws. AP and lateral 
radiographs were obtained immediately postoperatively to 
document the reduction and ﬁxation accuracy. 
Animals were randomized to receive either placebo 
(sugar pill) or rofecoxib (Merck and Co., Inc., Whitehouse 
Station, NJ) 12.5 mg/day administered orally once daily 
for 4 weeks and then discontinued. The tablet was covered 
in a tasty jelly and inserted directly into the rabbit’s mouth 
by a veterinary technician. 
The animals were housed individually in standard cages 
and provided fresh water and chow ad libitum. Animals 
were maintained for 28 days and then euthanized. Two 
additional animals that received placebo for the ﬁrst 
28 days were maintained for a total of 8 weeks in order to 
examine the osteotomy healing rate. Animals in which 
there was evidence of ﬁxation loss or infection were 
excluded from the study and humanely euthanized. 
Mechanical testing 
After sacriﬁce, both tibia were harvested and cleaned of soft 
tissues. The plate was removed and the ends of the bone 
potted in methacrylate. The specimens were secured in a 
custom ﬁxture for torsion testing and mounted in an Instron 
8511 Universal Testing Machine (Instron Corp., Norwood, 
MA). Specimens were tested in torsion at a rate of 10� per 
minute until failure. Rotational displacement and torque data 
were collected at 100 Hz. Maximum torque was measured 
directly from the data, and torsional stiffness was calculated 
from a regression of the linear portion of the torque versus 
angular displacement curve. The energy absorption to failure 
was also calculated as the area under the curve to the maxi­
mum value. The nonfractured contralateral intact femur was 
also tested to calculate normalized values of maximum tor­
que (percent maximum torque), stiffness (percent stiffness) 
and energy absorption to failure (percent energy) in order to 
reduce the inﬂuence of individual animal differences. 
The location of the failure with respect to the osteotomy 
site was recorded. Specimens that failed directly through 
the osteotomy site were classiﬁed as nonunions. Specimens 
that failed with a spiral fracture that crosses the fracture 
site were classiﬁed as a union. Specimens that show some 
evidence of bone bridging at the osteotomy site but that 
failed primarily through the osteotomy were be classiﬁed 
as an incomplete union [17]. 
Histology 
Following mechanical testing the specimens were removed 
from their potting ﬁxture, and the two fragments of the 
fracture reapproximated and held with narrow gauge wire. 
The specimens were ﬁxed in 4% paraformaldehyde with 
0.1 M phosphate buffer for 24 h. They were then defatted 
in 70% ethanol and decalciﬁed with 10% formic acid in 
citrate. The specimens were sliced in half longitudinally 
and embedded in parafﬁn. Parafﬁn sections (4 lm thick) 
were cut and stained with hematoxylin and eosin. 
Statistical analysis 
A pre hoc power analysis was performed based on an 
average control maximum torque to failure of 1.8 N m 
with a standard deviation of 0.2. Assuming a 20% differ­
ence, ﬁve animals per group were required to provide a 
80% power with an alpha level of 0.5. The means and 
standard deviations of the mechanical test data of osteo­
tomized and intact tibia were calculated. The 95% conﬁ­
dence interval for the mean was calculated for each group. 
An unpaired T test with unequal variance was used to 
compare the mechanical results of the rofecoxib-treated 
animals with the placebo-treated animals. 
Table 1 Mechanical test results of 4-week animals (mean and standard deviation) 
Treatment Side Maximum torque 
to failure (N m) 
Stiffness (N m/deg) Energy absorption to 
maximum torque (N m deg) 
Placebo (n = 5) Osteotomy 
Intact 
1.448 ? 0.386 
2.845 ± 0.383 
0.127 ± 0.059 
0.153 ± 0.026 
14.278 ± 4.453 
24.882 ± 6.033 
Rofecoxib (n = 7) Osteotomy 
Intact 
1.581 ± 0.302 
3.218 ± 0.535 
0.117 ± 0.057 
0.163 ± 0.022 
16.396 ? 2.786 
30.269 ? 7.256 
Results 
There was a high rate of peri-implant fracture during ani­
mal handling for administration of the study medication in 
the immediate postoperative period. Sixteen animals sus­
tained some peri-implant fracture or loss of ﬁxation, and 
were euthanized prior to study completion. Fifteen of these 
failures occurred during the ﬁrst 6 postoperative days, 
while one occurred at day 25. Loss of ﬁxation and healing 
with angulation and callus occurred in four other animals 
(three placebo, one rofecoxib). This was discovered on 
radiographs and examination at the time of sacriﬁce, and 
these specimens were excluded from the study. Twelve 
animals, maintained for 4 weeks, whose radiographs 
showed stable ﬁxation and no loss of alignment were used 
for mechanical analysis. Seven of these animals received 
rofecoxib, and ﬁve received placebo. 
All specimens failed with production of a spiral fracture. 
None of the specimens failed solely through the osteotomy 
site. In the 4-week animals, seven specimens failed par­
tially through the osteotomy site (3 placebo, 4 rofecoxib) 
and were categorized as incomplete unions. Five specimens 
(2 placebo, 3 rofecoxib) failed outside of the osteotomy 
site, usually though a distal screw hole, and were catego­
rized as unions. In the 8-week animals, one failed partially 
through the osteotomy site (incomplete union), and one 
failed outside the osteotomy site (union). 
At 4 weeks, the difference in the osteotomy site maxi­
mum torque to failure (Table 1) between the placebo- and 
the rofecoxib-treated animals was not signiﬁcant (p = 
0.54). The 95% conﬁdence interval of the osteotomy site 
maximum torque of the placebo group was 0.34–1.79 N m 
and of the rofecoxib group was 0.22–1.80 N m. When 
normalized to the intact side, the % maximum torque to 
failure of the osteotomy site was approximately 50% of the 
intact side for both the placebo and rofecoxib groups 
(Fig. 1). 
There was also no signiﬁcant difference between 
the placebo- and rofecoxib-treated groups for stiffness 
(p = 0.77) or for the energy absorption to maximum torque 
(p = 0.38). The 95% conﬁdence interval of the osteotomy 
site stiffness of the placebo group was 0.05–0.18 N m/deg 
and of the rofecoxib group was 0.04–0.16 N m/deg. The 
Fig. 1 Normalized values and standard deviations of mechanical test 
data: maximum torque, stiffness and energy absorption to maximum 
torque 
95% conﬁdence interval of the osteotomy site energy 
absorption to maximum torque for the placebo group was 
3.90–18.18 N m deg and for the rofecoxib group was 
2.06–18.46 N m deg. Normalized values for the stiffness 
came closer to approximating the intact side for both the 
placebo group and the rofecoxib group; however, the 
standard deviation was large. 
The maximum torque to failure of the two animals 
treated with placebo and maintained for a total of 8 weeks 
was 1.50 and 1.68 N m, which was not signiﬁcantly dif­
ferent from that seen in the placebo group at 4 weeks 
(average maximum torque 1.45 N m). 
Intramembranous bone formation, aligned perpendicular 
to the longitudinal axis, was found to be present in the 
narrow gap present between the ends of the osteotomy sites 
(Fig. 2). Evidence of osteoclastic cutting cones with for­
mation of new osteons was seen traversing the healed 
osteotomy sites (Fig. 3). Many of the specimens also 
showed some periosteal bone formation adjacent to the 
osteotomy site. 
Discussion 
In this rabbit tibial osteotomy model, we did not ﬁnd any 
signiﬁcant difference in the mechanical strength of direct 
fracture healing in animals treated with rofecoxib (12.5 mg 
daily dose) compared with placebo. However, we must 
caution that due to the small sample size we may not have 
been able to identify an actual difference between the 
Fig. 2 Intramembranous bone formation is seen ﬁlling the narrow 
gap present between the ends of the osteotomy sites in a placebo-
treated animal. Note that the bone is aligned perpendicular to the 
longitudinal axis. H&E, 920 
Fig. 3 New osteonal bone formation seen traversing the osteotomy 
site in a rofecoxib-treated animal. H&E, 940 
groups that may exist. The model selected for this study 
resulted in an unacceptably high complication rate, with a 
peri-implant fracture occurring in 16 animals and loss of 
ﬁxation leading to fracture angulation in an additional 4 
animals. The high complication rate with this animal model 
leads us to discourage its use for other studies examining 
primary (direct) bone healing. 
Absolute stability with interfragmentary compression is 
necessary to achieve primary (direct) bone healing. We 
attempted to achieve interfragmentary compression of the 
transverse osteotomy site by eccentric screw placement in 
the holes of the 2.7 mm dynamic compression plates. The 
presence of a small gap between the ends of the osteotomy 
site in most sections suggests that only limited interfrag­
mentary compression was achieved. In addition, the pres­
ence of periosteal bone formation suggests that there may 
have been some residual motion present at the osteotomy 
site. Alternatively this bone formation could be reactive 
due to inadvertent elevation of the periosteum around the 
osteotomy site. The presence of new osteonal bone for­
mation traversing the osteotomy site does suggest that the 
model does involve primary (direct) bone healing. Because 
many of the healed specimens contained a combination of 
primary (direct) bone healing and periosteal bone forma­
tion adjacent to the osteotomy site, our mechanical test data 
do not reﬂect the contribution of primary (direct) bone 
healing alone. 
As with any study there were problems and weaknesses 
associated with our investigation. The rofecoxib dosage 
selected was based on that used in prior studies; however, 
this may not be the appropriate effective dose due to dif­
ferences in absorption and metabolism in this species [9]. 
We chose to give the medication directly into the rabbit’s 
mouth, rather than in their feed, to ensure consistent 
administration. Many fractures occurred because of the 
rabbits’ forced hindlimb movements during medication 
administration. Even in animals in which catastrophic 
failure did not occur, loss of ﬁxation still occurred, leading 
to further exclusion of animals. Because of the difﬁculties 
using this model we did not have separate specimens 
available for a more thorough quantitative histologic 
evaluation. 
We examined only a single 4-week timepoint and may 
have missed subtle differences that rofecoxib may have had 
on the rate of fracture healing. We chose to examine the 
mechanical strength of healing at 4 weeks; however, other 
investigators have shown that the strength of plated rabbit 
tibia increased up to 6 weeks when tested in bending mode 
[18]. Because the process of primary bone healing is more 
gradual than secondary bone healing, the 4-week timepoint 
may have been too early since some other investigators 
have reported that osteonal bridging occurred at 6 weeks or 
later [16]. Difﬁculties with the animal model led us to 
abandon plans to study a larger group of animals at an 
8-week timepoint. 
There is conﬂicting information about the effect of Cox­
2 inhibition on fracture healing. Several pre-clinical studies 
have reported that Cox-2 inhibitors result in impaired 
fracture healing in animal models that heal by secondary 
(indirect) bone healing [5–8]. The magnitude of the detri­
mental effect of selective Cox-2 inhibitors on secondary 
fracture healing has been shown to be related to the dura­
tion of treatment [6]. Celecoxib administered during the 
ﬁrst 2 weeks after fracture signiﬁcantly impaired fracture 
healing in a rat secondary fracture healing model, whereas 
treatment prior to fracture or initiated 14 days after fracture 
did not impair secondary fracture healing [7]. 
Other studies, however, have reported that some Cox-2 
inhibitors have a less detrimental effects on fracture 
healing than non-speciﬁc nonsteroidal anti-inﬂammatories 
[19–22]. Brown and colleagues [19] found no decrease in 
the mechanical strength of rat femur fracture healing at 4, 8 
and 12 weeks in animals treated with celecoxib (3 mg/kg). 
While they did report that the celecoxib treated fractures 
appeared to have more ﬁbrous tissue than controls at 4 and 
8 weeks, they found no signiﬁcant difference in the degree 
of radiographic callus and the mechanical strength. Simon 
and colleagues reported that rofecoxib (4 mg/kg) signiﬁ­
cantly diminished the mechanical properties of a standard 
rat femur fracture at 8 weeks, but that celecoxib (3 mg/kg) 
showed no signiﬁcant difference in the mechanical prop­
erties of the fracture when compared to controls [20]. 
Karachalios et al. compared the effect of short-term 
administration of rofecoxib with non-selective NSAIDs 
and prednisolone on secondary fracture healing in a rabbit 
ulna osteotomy model. They administered rofecoxib 
(0.5 mg/kg/24 h) orally for 5 consecutive days. While all 
the biomechanical parameters of prednisolone, indomethi­
cin and meloxicam were signiﬁcantly lower than in the 
control group, only the fracture load values of rofecoxib 
were lower than the control. The histomorphometric 
parameters showed the least negative effects in the rofec­
oxib group. The investigators concluded that the short-term 
administration of rofecoxib had only a minor negative 
effect on bone healing [21]. 
Gerstenfeld and colleagues [23] characterized the 
expression of Cox-1 and Cox-2 mRNA in rat fracture 
calluses at timed intervals after fracture using real-time 
PCR. They found that Cox-2 mRNA levels showed peak 
expression during the ﬁrst 14 days of healing and returned 
to baseline levels by day 21. In addition they examined the 
effect of ketorolac (4 mg/kg), a non-speciﬁc NSAID, and 
two doses of parecoxib (0.3 and 1.5 mg/kg), a pro-drug of 
valdecoxib, in a rat femur fracture model. They found 
signiﬁcant reduction in the mechanical properties of ani­
mals treated with ketorolac at 21 days post-fracture. While 
the mean mechanical strength of the parecoxib-treated 
animals was less at 21 days, it was not statistically sig­
niﬁcant. They concluded that a Cox-2-selective NSAID 
such as parecoxib has only a small effect on delaying 
fracture healing, even at doses that are known to fully 
inhibit prostaglandin production. 
Utilizing a knockout mouse model, Zhang and col­
leagues [24] demonstrated that Cox-2 plays an essential 
role in both endochondral and intramembranous bone for­
mation during skeletal repair. The healing of stabilized 
tibia fractures was signiﬁcantly delayed in the Cox-2-/­
mice compared to the Cox-1-/- and the control wild-type 
mouse. The histology of the ﬁbrous nonunions in the Cox-
2-/- mice was characterized by a persistence of undif­
ferentiated mesenchyme and a marked reduction in 
osteogenesis. 
While some authors have expressed caution in the use of 
Cox-2 inhibitors in patients following fracture or other 
surgery requiring bone healing, others have questioned the 
clinical importance of the published animal data [25]. 
Similar concerns have been raised about the larger body of 
literature that has examined the effect of non-Cox-2 spe­
ciﬁc nonsteroidal anti-inﬂammatories on fracture healing in 
animal models. However, two clinical reports have raised 
concern about the effect of NSAIDs on fracture healing. In 
one study, patients who received indomethicin as prophy­
laxis for heterotopic ossiﬁcation following surgical treat­
ment of acetabular and long bone fractures had a 
signiﬁcantly greater rate of long bone nonunion (26 vs. 7%, 
p = 0.004) [26]. In a second retrospective study investi­
gators found a statistically signiﬁcant (p = 0.000001) 
association between nonunion of the femoral diaphysis and 
use of NSAIDs after injury [27]. 
While there may be other reasons to avoid the use of 
Cox-2 inhibitors in certain patients, the necessity for pri­
mary (direct) bone healing need not be a contraindication 
for their use. The immediate administration of a Cox-2­
speciﬁc inhibitor did not impair primary (direct) bone 
healing at the dose administered in this rabbit tibial oste­
otomy model. 
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